Department of Chemistry , Purdue University , West Lafayette , Indiana 47907 , United States.
Department of Pharmacokinetics, Pharmacodynamics, & Drug Metabolism , Merck & Co., Inc. , West Point , Pennsylvania 19486 , United States.
Anal Chem. 2019 Sep 3;91(17):11388-11396. doi: 10.1021/acs.analchem.9b02717. Epub 2019 Aug 16.
Glucuronidation, a common phase II biotransformation reaction, is one of the major and metabolism pathways of xenobiotics. In this process, glucuronic acid is conjugated to a drug or a drug metabolite via a carboxylic acid, a hydroxy, or an amino group to form acyl-, -, and/or -glucuronide metabolites, respectively. This process is traditionally thought to be a detoxification pathway. However, some acyl-glucuronides react with biomolecules , which may result in immune-mediated idiosyncratic drug toxicity (IDT). In order to avoid this, one may attempt in early drug discovery to modify the lead compounds in such a manner that they then have a lower probability of forming reactive acyl-glucuronide metabolites. Because most drugs or drug candidates bear multiple functionalities, e.g., hydroxy, amino, and carboxylic acid groups, glucuronidation can occur at any of those. However, differentiation of isomeric acyl-, , and -glucuronide derivatives of drugs is challenging. In this study, gas-phase ion-molecule reactions between deprotonated glucuronide metabolites and BF followed by collision-activated dissociation (CAD) in a linear quadrupole ion trap mass spectrometer were demonstrated to enable the differentiation of acyl-, , and -glucuronides. Only deprotonated -glucuronides and deprotonated, migrated acyl-glucuronides form the two diagnostic product ions: a BF adduct that has lost two HF molecules, [M - H + BF - 2HF], and an adduct formed with two BF molecules that has lost three HF molecules, [M - H + 2BF - 3HF]. These product ions were not observed for deprotonated -glucuronides and unmigrated, deprotonated acyl-glucuronides. Upon CAD of the [M - H + 2BF - 3HF] product ion, a diagnostic fragment ion is formed via the loss of 2-fluoro-1,3,2-dioxaborale (MW of 88 Da) only in the case of deprotonated, migrated acyl-glucuronides. Therefore, this method can be used to unambiguously differentiate acyl-, , and -glucuronides. Further, coupling this methodology with HPLC enables the differentiation of unmigrated 1-β-acyl-glucuronides from the isomeric acyl-glucuronides formed upon acyl migration. Quantum chemical calculations at the M06-2X/6-311++G(d,p) level of theory were employed to probe the mechanisms of the reactions of interest.
结合物形成,是一种常见的 II 相生物转化反应,是外源物质代谢的主要途径之一。在这个过程中,通过羧酸、羟基或氨基,将葡萄糖醛酸连接到药物或药物代谢物上,分别形成酰基-、-和/-葡萄糖醛酸代谢物。这个过程传统上被认为是解毒途径。然而,一些酰基葡萄糖醛酸与生物分子反应,可能导致免疫介导的特异药物毒性(IDT)。为了避免这种情况,人们可能会在早期药物发现中尝试以这样的方式修饰先导化合物,使它们形成反应性酰基葡萄糖醛酸代谢物的概率降低。由于大多数药物或候选药物具有多种功能,例如羟基、氨基和羧酸基团,因此葡萄糖醛酸化可以在任何一个基团上发生。然而,区分药物的异构酰基-、-和/-葡萄糖醛酸衍生物具有挑战性。在这项研究中,通过在直线四极离子阱质谱仪中进行去质子化葡萄糖醛酸代谢物与 BF 的气相离子-分子反应,以及随后的碰撞激活解离(CAD),证明了区分酰基-、-和/-葡萄糖醛酸的方法。只有去质子化的 -葡萄糖醛酸和迁移的去质子化酰基葡萄糖醛酸形成两种诊断产物离子:失去两个 HF 分子的 BF 加合物,[M - H + BF - 2HF],以及与两个 BF 分子形成、失去三个 HF 分子的加合物,[M - H + 2BF - 3HF]。这些产物离子未观察到去质子化的 -葡萄糖醛酸和未迁移的、去质子化的酰基葡萄糖醛酸。当 CAD 作用于 [M - H + 2BF - 3HF]产物离子时,仅在去质子化、迁移的酰基葡萄糖醛酸的情况下,通过失去 2-氟-1,3,2-二氧代硼烷(MW 为 88 Da)形成诊断片段离子。因此,该方法可用于明确区分酰基-、-和/-葡萄糖醛酸。此外,将这种方法与 HPLC 相结合,可以区分酰基迁移形成的非迁移 1-β-酰基葡萄糖醛酸与异构酰基葡萄糖醛酸。采用 M06-2X/6-311++G(d,p)理论水平的量子化学计算,探究了感兴趣反应的机制。